Axsome Therapeutics (AXSM) Raw Materials (2022 - 2026)

Axsome Therapeutics (AXSM) has 5 years of Raw Materials data on file, last reported at $11.9 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials rose 2.81% year-over-year to $11.9 million; the trailing twelve-month figure through Mar 2026 stood at $11.9 million (up 2.81% YoY), and the FY2025 full-year result was $10.4 million, up 8.76% from the prior year.
• Raw Materials advanced to $11.9 million in Q1 2026, from $10.4 million in the prior quarter.
• In the past five years, Raw Materials ranged from a high of $12.4 million in Q3 2025 to a low of $2.1 million in Q3 2022.
• A 5-year average of $7.4 million and a median of $7.7 million in 2024 frame the typical range for Raw Materials.
• Across the five-year window, Raw Materials soared 123.78% in 2023 and grew 2.81% in 2026, its largest moves.
• Tracing AXSM's Raw Materials over 5 years: stood at $2.5 million in 2022, then surged by 123.78% to $5.5 million in 2023, then soared by 72.41% to $9.5 million in 2024, then rose by 8.76% to $10.4 million in 2025, then grew by 14.26% to $11.9 million in 2026.
• Business Quant data shows AXSM's Raw Materials at $11.9 million in Q1 2026, $10.4 million in Q4 2025, and $12.4 million in Q3 2025.